The content is available as a PDF (314.9 KB).
. 2020 Jul 29:bqaa121. doi: 10.1210/endocr/bqaa121
COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy
Daniel I Spratt
1,✉, Rachel J Buchsbaum
2
Daniel I Spratt, MD
1
The Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Maine Medical Center, Portland ME
Find articles by Daniel I Spratt
Rachel J Buchsbaum, MD
2
Division of Hematology/Oncology, Tufts University School of Medicine, Boston MA (RB)
Find articles by Rachel J Buchsbaum
1
The Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Maine Medical Center, Portland ME
2
Division of Hematology/Oncology, Tufts University School of Medicine, Boston MA (RB)
✉
Corresponding author: Daniel Spratt, MD, Division of Reproductive Endocrinology and Infertility, Maine Medical Center, Portland, ME 04102, Phone: 207-771-5549, Email: spratd@mmc.org
Received 2020 May 28.
Keywords: COVID-19, coronavirus, hypercoagulability, oral contraceptives, estrogen therapy, pregnancy
© Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC7454527 PMID: 32725207